DelveInsight’s “Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Bronchopulmonary Dysplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchopulmonary Dysplasia Market Forecast
Some of the key facts of the Bronchopulmonary Dysplasia Market Report:
- The Bronchopulmonary Dysplasia market size was valued approximately USD 0.28 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The total incident cases of Bronchopulmonary Dysplasia in the 7MM was found to be approximately 17,058 cases in 2021. These cases are expected to increase by 2032
- Among 7MM, the United States had the highest incident cases of Bronchopulmonary Dysplasia with approximately 13,222 cases in 2021
- Among EU4 and the UK, Germany had the highest incident population of Bronchopulmonary Dysplasia with 944 cases, followed by France with 931 cases in 2021. On the other hand, Italy had the lowest incident population
- Key Bronchopulmonary Dysplasia Companies: Oak Hill Bio, Advent Therapeutics Inc, Airway Therapeutics LLC, Ayuvis Research Inc, Chiesi Farmaceutici SpA, Insmed Inc, Laboratoire Aguettant SA, MediPost Co Ltd, Meridigen Biotech Co Ltd, Orphanix GmbH, Radikal Therapeutics Inc, Syntrix Biosystems Inc, Takeda Pharmaceutical Co Ltd, The Cell Factory BVBA, Trimunocor Ltd, United Therapeutics Corp, Windtree Therapeutics Inc, and others
- Key Bronchopulmonary Dysplasia Therapies: OHB-607, CHF5633, PNEUMOSTEM, AT-100, Inhaled Nitric Oxide, Curosurf, Sildenafil, recombinant human CC10, OHB-607, and others
- The Bronchopulmonary Dysplasia epidemiology based on gender analyzed that severity‐specific data reveal the highest number of preterm infants have mild Bronchopulmonary Dysplasia
- The Bronchopulmonary Dysplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchopulmonary Dysplasia pipeline products will significantly revolutionize the Bronchopulmonary Dysplasia market dynamics.
Get a Free sample for the Bronchopulmonary Dysplasia Market Report-
https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market
Bronchopulmonary Dysplasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Bronchopulmonary Dysplasia Epidemiology Segmentation:
The Bronchopulmonary Dysplasia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Bronchopulmonary Dysplasia
- Prevalent Cases of Bronchopulmonary Dysplasia by severity
- Gender-specific Prevalence of Bronchopulmonary Dysplasia
- Diagnosed Cases of Episodic and Chronic Bronchopulmonary Dysplasia
Download the report to understand which factors are driving Bronchopulmonary Dysplasia epidemiology trends @ Bronchopulmonary Dysplasia Epidemiology Forecast
Bronchopulmonary Dysplasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchopulmonary Dysplasia market or expected to get launched during the study period. The analysis covers Bronchopulmonary Dysplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bronchopulmonary Dysplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Bronchopulmonary Dysplasia Therapies and Key Companies
- OHB-607: Oak Hill Bio/Takeda
- CHF5633: Chiesi Farmaceutici
- PNEUMOSTEM: Medipost
- AT-100: Airway Therapeutics
Discover more about therapies set to grab major Bronchopulmonary Dysplasia market share @ Bronchopulmonary Dysplasia Treatment Market
Bronchopulmonary Dysplasia Market Drivers
- Improved disease understanding
- Increase in Bronchopulmonary Dysplasia patient pool
- Biomarkers
- Limited late-stage drugs in the pipeline
Bronchopulmonary Dysplasia Market Barriers
- The discrepancy in Epidemiology Data
- Lack of adequate clinical data
- High use of Non-pharmacological therapy
- Limitations in Animal Model
Scope of the Bronchopulmonary Dysplasia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Bronchopulmonary Dysplasia Companies: Oak Hill Bio, Advent Therapeutics Inc, Airway Therapeutics LLC, Ayuvis Research Inc, Chiesi Farmaceutici SpA, Insmed Inc, Laboratoire Aguettant SA, MediPost Co Ltd, Meridigen Biotech Co Ltd, Orphanix GmbH, Radikal Therapeutics Inc, Syntrix Biosystems Inc, Takeda Pharmaceutical Co Ltd, The Cell Factory BVBA, Trimunocor Ltd, United Therapeutics Corp, Windtree Therapeutics Inc, and others
- Key Bronchopulmonary Dysplasia Therapies: OHB-607, CHF5633, PNEUMOSTEM, AT-100, Inhaled Nitric Oxide, Curosurf, Sildenafil, recombinant human CC10, OHB-607, and others
- Bronchopulmonary Dysplasia Therapeutic Assessment: Bronchopulmonary Dysplasia current marketed and Bronchopulmonary Dysplasia emerging therapies
- Bronchopulmonary Dysplasia Market Dynamics: Bronchopulmonary Dysplasia market drivers and Bronchopulmonary Dysplasia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Bronchopulmonary Dysplasia Unmet Needs, KOL’s views, Analyst’s views, Bronchopulmonary Dysplasia Market Access and Reimbursement
To know more about Bronchopulmonary Dysplasia companies working in the treatment market, visit @ Bronchopulmonary Dysplasia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Bronchopulmonary Dysplasia Market Report Introduction
2. Executive Summary for Bronchopulmonary Dysplasia
3. SWOT analysis of Bronchopulmonary Dysplasia
4. Bronchopulmonary Dysplasia Patient Share (%) Overview at a Glance
5. Bronchopulmonary Dysplasia Market Overview at a Glance
6. Bronchopulmonary Dysplasia Disease Background and Overview
7. Bronchopulmonary Dysplasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Bronchopulmonary Dysplasia
9. Bronchopulmonary Dysplasia Current Treatment and Medical Practices
10. Bronchopulmonary Dysplasia Unmet Needs
11. Bronchopulmonary Dysplasia Emerging Therapies
12. Bronchopulmonary Dysplasia Market Outlook
13. Country-Wise Bronchopulmonary Dysplasia Market Analysis (2019–2032)
14. Bronchopulmonary Dysplasia Market Access and Reimbursement of Therapies
15. Bronchopulmonary Dysplasia Market Drivers
16. Bronchopulmonary Dysplasia Market Barriers
17. Bronchopulmonary Dysplasia Appendix
18. Bronchopulmonary Dysplasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services